Kyowa Kirin Announces EU Approval for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH) apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Positive CHMP opinion for self-administered Crysvita
10th May 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Kyowa Kirin’s Crysvita for a new self-administration option to treat the rare metabolic bone disease X-linked hypophosphataemia (XLH).
XLH is a rare, genetic disease that causes bone, muscle and joint abnormalities. Although the condition is not life-threatening, it may reduce an individual’s quality of life with a life-long and progressive burden.
Currently, Crysvita (burosumab) is administered by subcutaneous injection, and will still need to be initiated by an experienced physician if the new self-administration option is ultimately approved.